MENLO PARK, Calif., March 17, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that two abstracts describing non-clinical data on imetelstat have been accepted for presentation as posters at the 2016 American Association of Cancer Research (AACR) Annual Meeting to be held in New Orleans, Louisiana from April 16-20, 2016. The abstracts are available on the AACR website at www.aacr.org.
Poster Presentations at AACR Annual Meeting
Session Title: Cell Cycle Control and Checkpoints
Session Date: Tuesday, April 19, 2016
Session Time: 8:00 a.m. ET -12:00 p.m. ET
Title: Impact of hypomethylating agents on hTERT expression and synergistic effect in combination with imetelstat, a telomerase inhibitor, in AML cell lines (Abstract #2731)
Title: Myelosuppression in patients treated with the telomerase inhibitor imetelstat is not mediated through activation of toll-like receptors (Abstract #2732)
In accordance with AACR policies, abstracts submitted to the AACR Annual Meeting are embargoed from the time of submission. To be eligible for presentation at the AACR Annual Meeting, information contained in the abstract, as well as additional data and information to be presented at the Annual Meeting, may not be made public before the abstract has been presented in connection with the AACR Annual Meeting.
Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.